

Title (en)

LACTOFERRIN FOR ORAL INHALATION USE FOR THE TREATMENT OF A DISEASE CAUSED BY A SARS-CORONA VIRUS

Title (de)

LACTOFERRIN ZUR ORALEN INHALATION ZUR BEHANDLUNG EINER DURCH EIN SARS-CORONA-VIRUS VERURSACHTEN KRANKHEIT

Title (fr)

LACTOFERRINE POUR UNE UTILISATION PAR INHALATION ORALE POUR LE TRAITEMENT D'UNE MALADIE PROVOQUÉE PAR UN CORONAVIRUS SARS

Publication

EP 4117712 A1 20230118 (EN)

Application

EP 21717209 A 20210309

Priority

- IT 202000005026 A 20200309
- IB 2021051941 W 20210309

Abstract (en)

[origin: WO2021181261A1] The present invention relates to a composition comprising lactoferrin for inhalation use in the treatment of viral infections of the respiratory system, and related symptoms or disorders, caused by a SARS- coronavirus (e.g. COVID-19 disease). In addition, the present invention relates to a device for the administration - through the inhalation route - of said composition comprising lactoferrin and the use thereof in said methods for the treatment of viral infections.

IPC 8 full level

A61K 38/40 (2006.01); **A61K 9/00** (2006.01); **A61K 31/198** (2006.01); **A61M 15/00** (2006.01); **A61P 31/12** (2006.01)

CPC (source: EP)

A61K 9/0075 (2013.01); **A61K 31/198** (2013.01); **A61K 31/728** (2013.01); **A61K 38/40** (2013.01); **A61K 47/26** (2013.01); **A61P 31/12** (2017.12); **A61K 47/36** (2013.01); **A61M 11/003** (2014.02); **A61M 15/0028** (2013.01); **A61M 2202/064** (2013.01)

Citation (search report)

See references of WO 2021181261A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

Designated extension state (EPC)

BA ME

Designated validation state (EPC)

KH MA MD TN

DOCDB simple family (publication)

WO 2021181261 A1 20210916; EP 4117712 A1 20230118; IT 202000005026 A1 20210909

DOCDB simple family (application)

IB 2021051941 W 20210309; EP 21717209 A 20210309; IT 202000005026 A 20200309